STOCK TITAN

Rani Therapeutics to Participate in the H.C. Wainwright BioConnect Investor Conference at NASDAQ

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Rani Therapeutics, a clinical-stage biotherapeutics company, announced that its CEO, Talat Imran, will participate in a fireside chat at the H.C. Wainwright BioConnect Investor Conference on May 2, 2023, at 11:30 AM ET. The event will showcase Rani's innovative approach to oral delivery of biologics and drugs, primarily through its patented RaniPill® capsule technology, which aims to replace traditional injection methods. Interested parties can access the live webcast from the Investor Relations section of Rani Therapeutics' website, with a replay available post-event.

Rani Therapeutics is dedicated to enhancing drug delivery systems and has successfully conducted multiple preclinical and clinical studies to validate the safety and efficacy of its oral dosing technologies.

Positive
  • None.
Negative
  • None.

SAN JOSE, Calif., April 25, 2023 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced the company’s Chief Executive Officer, Talat Imran, will participate in a fireside chat at the H.C. Wainwright BioConnect Investor Conference on Tuesday, May 2, 2023 at 11:30 am E.T.

Interested parties can access the live webcast for this conference from the Investor Relations section of the company's website at www.ranitherapeutics.com. The webcast replay will be available after the conclusion of the presentation.

Rani Therapeutics

Rani Therapeutics is a clinical-stage biotherapeutics company focused on advancing technologies to enable the development of orally administered biologics and drugs. Rani has developed the RaniPill® capsule, which is a novel, proprietary and patented platform technology, intended to replace subcutaneous injection or intravenous infusion of biologics and drugs with oral dosing. Rani has successfully conducted several preclinical and clinical studies to evaluate safety, tolerability and bioavailability using RaniPill® capsule technology. For more information, visit ranitherapeutics.com.

Investor Contact:

investors@ranitherapeutics.com

Media Contact:

media@ranitherapeutics.com

 


FAQ

What conference is Rani Therapeutics participating in on May 2, 2023?

Rani Therapeutics will participate in the H.C. Wainwright BioConnect Investor Conference.

Who is the CEO of Rani Therapeutics?

The CEO of Rani Therapeutics is Talat Imran.

What is the focus of Rani Therapeutics?

Rani Therapeutics focuses on the oral delivery of biologics and drugs using its RaniPill® capsule technology.

Where can I watch the Rani Therapeutics conference webcast?

The live webcast can be accessed from the Investor Relations section of Rani Therapeutics' website.

What time will the Rani Therapeutics fireside chat begin?

The fireside chat will begin at 11:30 AM ET on May 2, 2023.

Rani Therapeutics Holdings, Inc.

NASDAQ:RANI

RANI Rankings

RANI Latest News

RANI Stock Data

73.75M
32.29M
30.61%
10.14%
8.64%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
SAN JOSE